Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (259)
  • Open Access

    REVIEW

    Targeting brain tumors with innovative nanocarriers: bridging the gap through the blood-brain barrier

    KARAN WADHWA1, PAYAL CHAUHAN1, SHOBHIT KUMAR2, RAKESH PAHWA3,*, RAVINDER VERMA4, RAJAT GOYAL5, GOVIND SINGH1, ARCHANA SHARMA6, NEHA RAO3, DEEPAK KAUSHIK1,*

    Oncology Research, Vol.32, No.5, pp. 877-897, 2024, DOI:10.32604/or.2024.047278

    Abstract Background: Glioblastoma multiforme (GBM) is recognized as the most lethal and most highly invasive tumor. The high likelihood of treatment failure arises from the presence of the blood-brain barrier (BBB) and stem cells around GBM, which avert the entry of chemotherapeutic drugs into the tumor mass. Objective: Recently, several researchers have designed novel nanocarrier systems like liposomes, dendrimers, metallic nanoparticles, nanodiamonds, and nanorobot approaches, allowing drugs to infiltrate the BBB more efficiently, opening up innovative avenues to prevail over therapy problems and radiation therapy. Methods: Relevant literature for this manuscript has been collected from a comprehensive and systematic search of… More > Graphic Abstract

    Targeting brain tumors with innovative nanocarriers: bridging the gap through the blood-brain barrier

  • Open Access

    REVIEW

    A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases

    NILAM BHUSARE, MAUSHMI KUMAR*

    Oncology Research, Vol.32, No.5, pp. 849-875, 2024, DOI:10.32604/or.2024.047042

    Abstract Glioblastoma, the most aggressive form of brain tumor, poses significant challenges in terms of treatment success and patient survival. Current treatment modalities for glioblastoma include radiation therapy, surgical intervention, and chemotherapy. Unfortunately, the median survival rate remains dishearteningly low at 12–15 months. One of the major obstacles in treating glioblastoma is the recurrence of tumors, making chemotherapy the primary approach for secondary glioma patients. However, the efficacy of drugs is hampered by the presence of the blood-brain barrier and multidrug resistance mechanisms. Consequently, considerable research efforts have been directed toward understanding the underlying signaling pathways involved in glioma and developing… More > Graphic Abstract

    A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases

  • Open Access

    REVIEW

    Targeting KRAS in pancreatic cancer

    SANDRA STICKLER, BARBARA RATH, GERHARD HAMILTON*

    Oncology Research, Vol.32, No.5, pp. 799-805, 2024, DOI:10.32604/or.2024.045356

    Abstract Pancreatic cancer has a dismal prognosis due to late detection and lack of efficient therapies. The Kirsten rat sarcoma virus (KRAS) oncogene is mutated in up to 90% of all pancreatic ductal adenocarcinomas (PDACs) and constitutes an attractive target for therapy. However, the most common KRAS mutations in PDAC are G12D (44%), G12V (34%) and G12R (20%) that are not amenable to treatment by KRAS G12C-directed cysteine-reactive KRAS inhibitors such as Sotorasib and Adagrasib that exhibit clinical efficacy in lung cancer. KRAS G12C mutant pancreatic cancer has been treated with Sotorasib but this mutation is detected only in 2%–3% of… More >

  • Open Access

    ARTICLE

    Puerarin mediated miR-30b-5p targeting fibroblast activation protein against oral submucous fibrosis

    SAIFEI XIE1,2,4, HUI XIE2,*, JINCAI GUO3, JIN TAN4, YULIN YU1, MINYI ZHANG1, SHANG WEN1

    BIOCELL, Vol.48, No.4, pp. 591-599, 2024, DOI:10.32604/biocell.2024.046691

    Abstract Background: Puerarin (Pue) has been reported to be a natural active ingredient with multiple antifibrotic properties. This work aimed at exploring the function of Pue in oral submucous fibrosis (OSF) treatment. Methods: Human oral mucosa fibroblasts (hOMF) were induced with transforming growth factor beta1 (TGF-β1) and intervened with Pue. Expressions of fibrosis-related markers were analyzed by Western blot and IF staining. Cell viability was characterized by the CCK-8 assay. Expressions of miR-30 family members were quantified by qRT-PCR. The correlation between fibroblast activation protein (FAP) and miR-30 family expression was evaluated by the Pearson correlation coefficient. Bioinformatics prediction and dual-luciferase… More > Graphic Abstract

    Puerarin mediated miR-30b-5p targeting fibroblast activation protein against oral submucous fibrosis

  • Open Access

    ARTICLE

    Missing Value Imputation for Radar-Derived Time-Series Tracks of Aerial Targets Based on Improved Self-Attention-Based Network

    Zihao Song, Yan Zhou*, Wei Cheng, Futai Liang, Chenhao Zhang

    CMC-Computers, Materials & Continua, Vol.78, No.3, pp. 3349-3376, 2024, DOI:10.32604/cmc.2024.047034

    Abstract The frequent missing values in radar-derived time-series tracks of aerial targets (RTT-AT) lead to significant challenges in subsequent data-driven tasks. However, the majority of imputation research focuses on random missing (RM) that differs significantly from common missing patterns of RTT-AT. The method for solving the RM may experience performance degradation or failure when applied to RTT-AT imputation. Conventional autoregressive deep learning methods are prone to error accumulation and long-term dependency loss. In this paper, a non-autoregressive imputation model that addresses the issue of missing value imputation for two common missing patterns in RTT-AT is proposed. Our model consists of two… More >

  • Open Access

    ARTICLE

    Degradation of FAK-targeting by proteolytic targeting chimera technology to inhibit the metastasis of hepatocellular carcinoma

    XINFENG ZHANG1,2,#, SHUANG LI2,#, MEIRU SONG1,2, YUE CHEN3, LIANGZHENG CHANG3, ZHERUI LIU4, HONGYUAN DAI3, YUTAO WANG4, GANGQI YANG3, YUN JIANG5,6,*, YINYING LU1,2,*

    Oncology Research, Vol.32, No.4, pp. 679-690, 2024, DOI:10.32604/or.2024.046231

    Abstract Liver cancer is a prevalent malignant cancer, ranking third in terms of mortality rate. Metastasis and recurrence primarily contribute to the high mortality rate of liver cancer. Hepatocellular carcinoma (HCC) has low expression of focal adhesion kinase (FAK), which increases the risk of metastasis and recurrence. Nevertheless, the efficacy of FAK phosphorylation inhibitors is currently limited. Thus, investigating the mechanisms by which FAK affects HCC metastasis to develop targeted therapies for FAK may present a novel strategy to inhibit HCC metastasis. This study examined the correlation between FAK expression and the prognosis of HCC. Additionally, we explored the impact of… More >

  • Open Access

    ARTICLE

    miR-125b reverses cisplatin resistance by regulating autophagy via targeting RORA/BNIP3L axis in lung adenocarcinoma

    LEI LIU1, NA GUO1, XIANGLING LI2, QIAN XU2, RUILONG HE3, LIMIN CHENG4, CHUNYAN DANG3, XINYU BAI3, YIYING BAI3, XIN WANG3, QIANHUI CHEN3, LI ZHANG3,*

    Oncology Research, Vol.32, No.4, pp. 643-658, 2024, DOI:10.32604/or.2023.044491

    Abstract The platinum-based chemotherapy is one of the most frequently used treatment protocols for lung adenocarcinoma (LUAD), and chemoresistance, however, usually results in treatment failure and limits its application in the clinic. It has been shown that microRNAs (miRNAs) play a significant role in tumor chemoresistance. In this study, miR-125b was identified as a specific cisplatin (DDP)-resistant gene in LUAD, as indicated by the bioinformatics analysis and the real-time quantitative PCR assay. The decreased serum level of miR-125b in LUAD patients was correlated with the poor treatment response rate and short survival time. MiR-125b decreased the A549/DDP proliferation, and the multiple… More >

  • Open Access

    ARTICLE

    Dual ligand-targeted Pluronic P123 polymeric micelles enhance the therapeutic effect of breast cancer with bone metastases

    HUAN GAO1,2, JIE ZHANG1, TONY G. KLEIJN1,3,4, ZHAOYONG WU5, BING LIU1,6, YUJIN MA6, BAOYUE DING1,*, DONGFENG YIN2,*

    Oncology Research, Vol.32, No.4, pp. 769-784, 2024, DOI:10.32604/or.2023.044276

    Abstract Bone metastasis secondary to breast cancer negatively impacts patient quality of life and survival. The treatment of bone metastases is challenging since many anticancer drugs are not effectively delivered to the bone to exert a therapeutic effect. To improve the treatment efficacy, we developed Pluronic P123 (P123)-based polymeric micelles dually decorated with alendronate (ALN) and cancer-specific phage protein DMPGTVLP (DP-8) for targeted drug delivery to breast cancer bone metastases. Doxorubicin (DOX) was selected as the anticancer drug and was encapsulated into the hydrophobic core of the micelles with a high drug loading capacity (3.44%). The DOX-loaded polymeric micelles were spherical,… More > Graphic Abstract

    Dual ligand-targeted Pluronic P123 polymeric micelles enhance the therapeutic effect of breast cancer with bone metastases

  • Open Access

    ARTICLE

    Identifying and validating MMP family members (MMP2, MMP9, MMP12, and MMP16) as therapeutic targets and biomarkers in kidney renal clear cell carcinoma (KIRC)

    KUNLUN LI1, DANDAN LI2, BARBOD HAFEZ3,*, MOUNIR M. SALEM BEKHIT4, YOUSEF A. BIN JARDAN4, FARS KAED ALANAZI4, EHAB I. TAHA4, SAYED H. AUDA4, FAIQAH RAMZAN5,*, MUHAMMAD JAMIL6

    Oncology Research, Vol.32, No.4, pp. 737-752, 2024, DOI:10.32604/or.2023.042925

    Abstract Kidney Renal Clear Cell Carcinoma (KIRC) is a malignant tumor that carries a substantial risk of morbidity and mortality. The MMP family assumes a crucial role in tumor invasion and metastasis. This study aimed to uncover the mechanistic relevance of the MMP gene family as a therapeutic target and diagnostic biomarker in Kidney Renal Clear Cell Carcinoma (KIRC) through a comprehensive approach encompassing both computational and molecular analyses. STRING, Cytoscape, UALCAN, GEPIA, OncoDB, HPA, cBioPortal, GSEA, TIMER, ENCORI, DrugBank, targeted bisulfite sequencing (bisulfite-seq), conventional PCR, Sanger sequencing, and RT-qPCR based analyses were used in the present study to analyze MMP… More >

  • Open Access

    REVIEW

    The heterogeneity of tumor-associated macrophages and strategies to target it

    HAO LV1, BO ZHU1,2, DEGAO CHEN1,2,*

    BIOCELL, Vol.48, No.3, pp. 363-378, 2024, DOI:10.32604/biocell.2023.046367

    Abstract Tumor-associated macrophages (TAMs) are emerging as targets for tumor therapy because of their primary role in promoting tumor progression. Several studies have been conducted to target TAMs by reducing their infiltration, depleting their numbers, and reversing their phenotypes to suppress tumor progression, leading to the development of drugs in preclinical and clinical trials. However, the heterogeneous characteristics of TAMs, including their ontogenetic and functional heterogeneity, limit their targeting. Therefore, in-depth exploration of the heterogeneity of TAMs, combined with immune checkpoint therapy or other therapeutic modalities could improve the efficiency of tumor treatment. This review focuses on the heterogeneous ontogeny and… More >

Displaying 1-10 on page 1 of 259. Per Page